Key Peripheral Neuritis Treatment Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly & Company
- Abbott Laboratories
- Janssen Pharmaceuticals (J&J)
- Novartis AG
- Boehringer Ingelheim
- GlaxoSmithKline (GSK)
- Vertex Pharmaceuticals
- Glenmark Pharmaceuticals
- Lupin Pharmaceuticals
- Astellas Pharma
- Merck & Co.
- Teva Pharmaceuticals
- Bayer AG
- Biogen Inc.
Therapeutic and treatment companies dominate the peripheral neuritis treatment market, with a robust portfolio of neuropathic pain treatments and a massive global marketing and distribution network. Companies are contributing heavily to ongoing R&D and also maintain diversified pipelines. Companies such as Glenmark and Lupin are focusing on generics to be sold in price-sensitive markets, while companies such as Astellas and Eisai keep the investments steady in neurology-related therapy. The competitive environment is a mix of giants of the pharmaceutical past with regionally strong companies heading toward innovation and access.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of the peripheral neuritis treatment market is estimated to reach approximately USD 2.1 billion.
The market size for the peripheral neuritis treatment market is projected to reach around USD 5.5 billion by the end of 2035, rising at a CAGR of about 5.5% during the forecast period (2026–2035).
The major global players in the market include Pfizer Inc., Eli Lilly & Company, Abbott Laboratories, Janssen Pharmaceuticals (Johnson & Johnson), and others.
Oral treatment modalities are expected to gain the largest share, accounting for approximately 62% of the Route of Administration segment by 2035.
The market in North America is expected to continue dominating the forecast period, accounting for a significant share of approximately 40%.
